SHINE has entered into an intellectual property license agreement with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), the company announced today.

According to a release, the agreement will provide SHINE with a global, exclusive license to a novel method for separating rare earth elements and producing lutetium-177 (Lu-177) for the treatment of cancer.

“The Lu-177-based cancer therapeutics under development now show tremendous promise for doing a huge amount of good in the world,” SHINE CEO Greg Piefer said in a statement. “SHINE is committed to ensuring there is enough Lu-177 to meet demand as more and more patients benefit from these products.”

The IOCB Prague separation method, which was developed by Dr. Miloslav Palasek, will allow SHINE to rapidly and efficiently separate Lu-177 from irradiated-ytterbium-176 targets, the company said.